- Home
- CEF vs NUVL Comparison
CEF vs NUVL Comparison
Compare CEF & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CEF
- NUVL
- Stock Information
- Founded
- CEF N/A
- NUVL 2017
- Country
- CEF
- NUVL United States
- Employees
- CEF N/A
- NUVL N/A
- Industry
- CEF
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- CEF
- NUVL Health Care
- Exchange
- CEF NYSE
- NUVL Nasdaq
- Market Cap
- CEF 5.4B
- NUVL 5.6B
- IPO Year
- CEF N/A
- NUVL 2021
- Fundamental
- Price
- CEF $29.06
- NUVL $74.61
- Analyst Decision
- CEF
- NUVL Strong Buy
- Analyst Count
- CEF 0
- NUVL 8
- Target Price
- CEF N/A
- NUVL $115.50
- AVG Volume (30 Days)
- CEF N/A
- NUVL 548.5K
- Earning Date
- CEF N/A
- NUVL 05-08-2025
- Dividend Yield
- CEF N/A
- NUVL N/A
- EPS Growth
- CEF N/A
- NUVL N/A
- EPS
- CEF N/A
- NUVL N/A
- Revenue
- CEF N/A
- NUVL N/A
- Revenue This Year
- CEF N/A
- NUVL N/A
- Revenue Next Year
- CEF N/A
- NUVL N/A
- P/E Ratio
- CEF N/A
- NUVL N/A
- Revenue Growth
- CEF N/A
- NUVL N/A
- 52 Week Low
- CEF N/A
- NUVL $55.54
- 52 Week High
- CEF N/A
- NUVL $113.51
- Technical
- Relative Strength Index (RSI)
- CEF 51.70
- NUVL 54.31
- Support Level
- CEF $28.98
- NUVL $70.25
- Resistance Level
- CEF $29.36
- NUVL $75.97
- Average True Range (ATR)
- CEF 0.28
- NUVL 3.09
- MACD
- CEF 0.00
- NUVL 0.13
- Stochastic Oscillator
- CEF 64.11
- NUVL 79.92
About CEF SPROTT PHYSICAL GOLD AND SILVER TR
Sprott Physical Gold and Silver Trust is a closed end mutual fund trust. The trust invests and holds all of its assets in physical gold and silver bullion and seeks to provide a secure, convenient and exchange-traded investment alternative for investors interested in holding physical bullion without the inconvenience that is typical of direct investment.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.